What are the indications and contraindications of pitobrutinib?

Pirtobrutinib (Pirtobrutinib, trade name Jaypirca, is an innovative drug mainly used to treat a variety of B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL). It inhibits the growth and proliferation of tumor cells by inhibiting the activity of Bruton's tyrosine kinase (BTK) and blocking the B cell receptor signaling pathway. Pitobrutinib has a wide range of indications and has achieved remarkable results in treatment, bringing new treatment hope to many patients.

In the treatment of CLL and SLL, pitobrutinib has shown strong inhibitory effects on tumor cells, helping to reduce the number of cancer cells and even achieve complete remission of the disease in some cases. For patients with MCL, pitobrutinib also performs well. It can not only reduce the number of cancer cells, but also eliminate signs of cancer, providing a new treatment option for patients with relapsed or refractory MCL. It is worth noting that pitobrutinib is also effective in patients who have been treated with covalent BTK inhibitors such as ibrutinib, acalabrutinib or zanbrutinib. This is due to its non-covalent and reversible BTK inhibitory properties, which can overcome resistance to traditional BTK inhibitors.

However, although pitobrutinib shows great potential in treatment, its contraindications and potential risks still need to be paid attention to during its use. Here are some key medication contraindications and precautions:

Infection is a serious side effect of pitobrutinib that needs to be alerted to. In clinical trials, patients have developed serious and fatal infections caused by bacteria, viruses or fungi, a significant number of which were grade 3 or higher. In addition, some patients developed opportunistic infections such as Pneumocystis jiroveci pneumonia. Therefore, for high-risk groups, such as those who are immunocompromised or have received organ transplants, preventive measures such as vaccination and antibiotics should be considered to reduce the risk of infection.

Bleeding is another adverse effect of concern after using pitobrutinib. Serious and fatal bleeding events have been reported in patients. Therefore, during the use of pitobrutinib, patients should be closely monitored for signs of bleeding, such as gum bleeding, epistaxis, skin ecchymosis, etc., and appropriate treatment measures should be taken.

Low blood cell counts are also one of the possible side effects of pitobrutinib. Patients may have lower than normal neutrophil, platelet, or red blood cell counts. This can lead to problems such as reduced immunity, increased risk of bleeding, or anemia. Therefore, healthcare providers will monitor patients' blood counts regularly throughout treatment and adjust treatment as needed.

Arrhythmias are another potential risk to be aware of after using pitobrutinib. Patients may develop arrhythmias such as atrial fibrillation and atrial flutter. In addition, patients have reported the occurrence of second primary cancers, including skin cancers. Therefore, patients should take sun protection measures and pay close attention to any abnormal changes in their body while using pitobrutinib.

Pitobrutinib may cause fetal harm in female patients of childbearing potential. Therefore, effective contraception should be used during use of pitobrutinib and for one week after the last dose to avoid unwanted pregnancy. Additionally, it is unclear whether pitobrutinib is safe and effective in children and its use in pediatric patients is not recommended.

In summary, as an innovative drug, pitobrutinib has demonstrated significant efficacy in the treatment ofCLL, SLL and MCL. However, it is still necessary to pay attention to its contraindications and potential risks during use. Patients should use drugs rationally under the guidance of a doctor and pay close attention to any abnormal changes in the body. At the same time, healthcare providers will also develop personalized treatment plans based on the patient's specific situation to ensure the safety and effectiveness of the treatment.

xa0

Reference: https://www.drugs.com/pirtobrutinib.html